Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Voyager Therapeutics (VYGR) FCF Margin (2016 - 2025)

Historic FCF Margin for Voyager Therapeutics (VYGR) over the last 11 years, with Q3 2025 value amounting to 233.25%.

  • Voyager Therapeutics' FCF Margin fell 1186400.0% to 233.25% in Q3 2025 from the same period last year, while for Sep 2025 it was 378.79%, marking a year-over-year decrease of 3613000.0%. This contributed to the annual value of 23.54% for FY2024, which is 534000.0% down from last year.
  • According to the latest figures from Q3 2025, Voyager Therapeutics' FCF Margin is 233.25%, which was down 1186400.0% from 660.88% recorded in Q2 2025.
  • Voyager Therapeutics' FCF Margin's 5-year high stood at 5197.26% during Q1 2022, with a 5-year trough of 2743.96% in Q2 2022.
  • Its 5-year average for FCF Margin is 120.0%, with a median of 114.6% in 2024.
  • Its FCF Margin has fluctuated over the past 5 years, first surged by 55305800bps in 2022, then crashed by -51154900bps in 2023.
  • Voyager Therapeutics' FCF Margin (Quarter) stood at 38.64% in 2021, then soared by 2100bps to 850.13% in 2022, then plummeted by -103bps to 27.22% in 2023, then plummeted by -759bps to 233.9% in 2024, then increased by 0bps to 233.25% in 2025.
  • Its FCF Margin was 233.25% in Q3 2025, compared to 660.88% in Q2 2025 and 593.12% in Q1 2025.